繁體
简体中文
繁體中文

Principal Healthcare Innovators Index ETF BTEC 深 滬

已收盤 07-31 16:00:00 美东时间

39.49

0.000

0.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 成交量 0股
  • 最 低 --
  • 昨 收 39.49
  • 總市值 4738.80万
  • 52周最高 41.10
  • 市盈率 靜 --
  • 換手率 0.00%
  • 52周最低 25.66
  • 委 比 0.00%
  • 總股本 120.00万
  • 歷史最高 73.38
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 22.34
  • 每 手 1
  • 風險率 0.00%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Abivax Statement on Short Seller Report

    Abivax SA issued a statement addressing a report by Scorpion Capital, which the company claims contains factually inaccurate and misleading statements. Abivax emphasizes the integrity of its clinical data, particularly from its Phase 3 ABTECT trials, and plans to file an NDA with the U.S. FDA by year-end. Scorpion Capital disclosed a short position in Abivax, highlighting its financial incentive to lower the company's share price. Abivax is a cli...

    11-20 21:33

  • Abivax reports 1H results

    Abivax press release (ABVX): 1H The Company had cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026. More on Abivax Abivax: Obefazimod Goes The Distance And So Does...

    09-22 04:09

  • Abivax raises $920M as underwriters fully exercise overallotment option

    Abivax (ABVX) said the underwriters of its U.S. public offering have fully exercised their option to purchase an additional 960K American Depositary Shares (ADSs). With the overallotment option fully ...

    07-02 19:06

  • Abivax SA prices upsized $800M ADS offering

    Abivax SA (ABVX) priced an upsized public offering of 6.4M ADSs at $125/ADS, raising ~$800M in gross proceeds. The offering size was increased from the previously announced $600M. The company granted ...

    07-01 20:56

  • Abivax launches $600M underwritten public offering

    Abivax SA (ABVX) on Tuesday announced the launch of an underwritten public offering of ~$600M of its American Depositary Shares, each representing one ordinary share of Abivax, nominal value €0.01 per...

    07-01 05:02

  • Abivax stock jumps on positive Phase 3 ulcerative colitis data

    Abivax SA (ABVX) shares surged Tuesday premarket after the biotech reported positive topline supplemental data from its Phase 3 ulcerative colitis maintenance program, delivering strong efficacy while...

    06-30 15:49

  • What's Going On With Abivax Stock On Thursday?

    Abivax's Phase 3 ulcerative colitis data met remission goals, but cancer cases in the study raised safety questions and analyst caution.

    06-04 22:35

  • Why Is Abivax Stock Sinking Tuesday?

    Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative colitis drug.

    06-02 20:49

  • Market-Moving News for June 2nd

    HPE: 30% | Hewlett Packard Enterprise shares are trading higher after the company reported better-than-expected Q2 financial results BJDX: 200% | Bluejay Diagnostics Announces Strategic Partnership With

    06-02 19:24

  • Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis

    Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary

    06-02 04:08